menu
    • menu
    [{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"ACT-709478","moa":"T-type calcium channel","graph1":"Neurology","graph2":"Phase I","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Idorsia Pharmaceuticals \/ Neurocrine Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Idorsia Pharmaceuticals \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"ACT-709478","moa":"T-type calcium channel","graph1":"Neurology","graph2":"Phase I","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Idorsia Pharmaceuticals \/ Neurocrine Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Idorsia Pharmaceuticals \/ Neurocrine Biosciences"}]

    Find Clinical Drug Pipeline Developments & Deals for ACT-709478

    Menu

    ACT-709478

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Idorsia Pharmaceuticals

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed

                            Idorsia Pharmaceuticals

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ACT-709478

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Neurocrine Biosciences

                            Deal Size : $410.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Neurocrine Biosciences exercises option to license Idorsia's novel treatment for rare pediatric epilepsy

                            Details : Neurocrine Biosciences to develop and commercialize ACT-709478, a clinical stage selective T-type calcium channel blocker for the treatment of a rare pediatric epilepsy.

                            Product Name : ACT-709478

                            Product Type : Other Small Molecule

                            Upfront Cash : $45.0 million

                            November 05, 2020

                            Lead Product(s) : ACT-709478

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Neurocrine Biosciences

                            Deal Size : $410.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Idorsia Pharmaceuticals

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed

                            Idorsia Pharmaceuticals

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ACT-709478

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Neurocrine Biosciences

                            Deal Size : $417.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilep...

                            Details : Under this agreement, Neurocrine Biosciences owns option to exclusively license ACT-709478, a clinical stage selective T-type calcium channel blocker for the treatment of epilepsy.

                            Product Name : ACT-709478

                            Product Type : Other Small Molecule

                            Upfront Cash : $45.0 million

                            October 01, 2020

                            Lead Product(s) : ACT-709478

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Neurocrine Biosciences

                            Deal Size : $417.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth